|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Management of hepatocellular carcinoma with portal vein thrombosis显示文摘Management of hepatocellular carcinoma(HCC) with portal vein thrombosis(PVT) is complex andrequires an understanding of multiple therapeutic options. PVT is present in 10%-40% of HCC at the time of diagnosis, and is an adverse prognostic factor. Management options are limited, as transplantation is generally contraindicated, and surgical resection is only rarely performed in select centers. Systemic medical therapy with sorafenib has been shown to modestly prolong survival. Transarterial chemoembolization has been performed in select cases but has shown a high incidence of complications. Emerging data on treatment of PVT with Y-90 radioembolization suggest that this modality is well-tolerated and associated with favorable overall survival. Current society guidelines do not yet specifically recommend radioembolization for patients with PVT, but this may change with the development of newer staging systems and treatment algorithms. In this comprehensive literature review, we present current and available management options with the relative advantages, disadvantages and contraindications of these treatment options with summarized data on overall survival. | Matthew Quirk Yun Hwan Kim Sammy Saab Edward Wolfgang Lee | 2015 | World Journal of Gastroenterology2015，21，12： | 12 |
| 2 | Reliability in endoscopic diagnosis of portal hypertensive gastropathy显示文摘AIM: To analyze reliability among endoscopists in diagnosing portal hypertensive gastropathy (PHG) and to determine which criteria from the most utilized classifications are the most suitable. METHODS: From January to July 2009, in an academic quaternary referral center at Santa Casa of S o Paulo Endoscopy Service, Brazil, we performed this singlecenter prospective study. In this period, we included 100 patients, including 50 sequential patients who had portal hypertension of various etiologies; who were previously diagnosed based on clinical, laboratory and imaging exams; and who presented with esophageal varices. In addition, our study included 50 sequentialpatients who had dyspeptic symptoms and were referred for upper digestive endoscopy without portal hypertension. All subjects underwent upper digestive endoscopy, and the images of the exam were digitally recorded. Five endoscopists with more than 15 years of experience answered an electronic questionnaire, which included endoscopic criteria from the 3 most commonly used Portal Hypertensive Gastropathy classifications (McCormack, NIEC and Baveno) and the presence of elevated or flat antral erosive gastritis. All five endosco- pists were blinded to the patients' clinical information, and all images of varices were deliberately excluded for the analysis. RESULTS: The three most common etiologies of portal hypertension were schistosomiasis (36%), alcoholic cirrhosis (20%) and viral cirrhosis (14%). Of the 50 patients with portal hypertension, 84% were Child A, 12% were Child B, 4% were Child C, 64% exhibited previous variceal bleeding and 66% were previously endoscopic treated. The endoscopic parameters, presence or absence of mosaic-like pattern, red point lesions and cherry-red spots were associated with high inter-observer reliability and high specificity for diagnosing Portal Hypertensive Gastropathy. Sensitivity, specificity and reliability for the diagnosis of PHG (%) were as follows: mosaic-like pattern (100; 92.21; High); fine pink speckling (56; 76.62; Unsatisfactory); superficial reddening (69.57; 66.23; Unsatisfactory); red-point lesions (47.83; 90.91; High); cherry-red spots (39.13; 96.10; High); isolated red marks (43.48; 88.31; High); and confluent red marks (21.74; 100; Unsatisfactory). Antral elevated erosive gastritis exhibited high reliability and high specificity with respect to the presence of portal hypertension (92%) and the diagnosis of portal hypertensive gastropathy (88.31%). CONCLUSION: The most suitable endoscopic criteria for the diagnosis of PHG were mosaic-like pattern, redpoint lesions and cherry-red spots with no subdivisions,which were associated with a high rate of inter-observer reliability. | George Fred Soares de Macedo Fabio Gon alves Ferreira Maurício Alves Ribeiro Luiz Arnaldo Szutan Mauricio Saab Assef Lucio Giovanni Battista Rossini | 2013 | World Journal of Gastrointestinal Endoscopy2013，5，7： | 9 |
| 3 | Nationwide trends and predictors of inpatient mortality in 83884 transjugular intrahepatic portosystemic shunt显示文摘AIM: To evaluate and validate the national trends and predictors of in-patient mortality of transjugular intrahepatic portosystemic shunt(TIPS) in 15 years.METHODS: Using the National Inpatient Sample which is a part of Health Cost and Utilization Project, we identified a discharge-weighted national estimate of 83884 TIPS procedures performed in the United States from 1998 to 2012 using international classification of diseases-9 procedural code 39.1. The demographic, hospital and co-morbility data were analyzed using a multivariant analysis. Using multi-nominal logistic regression analysis, we determined predictive factors related to increases in-hospital mortality. Comorbidity measures are in accordance to the Comorbidity Software designed by the Agency for Healthcare Research and Quality.RESULTS: Overall, 12.3% of patients died during hospitalization with downward trend in-hospitalmortality with the mean length of stay of 10.8 ± 13.1 d. Notable, African American patients(OR = 1.809 vs Caucasian patients, P < 0.001), transferred patients(OR = 1.347 vs non-transferred, P < 0.001), emergency admissions(OR = 3.032 vs elective cases, P < 0.001), patients in the Northeast region(OR = 1.449 vs West, P < 0.001) had significantly higher odds of inhospital mortality. Number of diagnoses and number of procedures showed positive correlations with in-hospital death(OR = 1.249 per one increase in number of procedures). Patients diagnosed with acute respiratory failure(OR = 8.246), acute kidney failure(OR = 4.359), hepatic encephalopathy(OR = 2.217) and esophageal variceal bleeding(OR = 2.187) were at considerably higher odds of in-hospital death compared with ascites(OR = 0.136, P < 0.001). Comorbidity measures with the highest odds of in-hospital death were fluid and electrolyte disorders(OR = 2.823), coagulopathy(OR = 2.016), and lymphoma(OR = 1.842).CONCLUSION: The overall mortality of the TIPS procedure is steadily decreasing, though the length of stay has remained relatively constant. Specific patient ethnicity, location, transfer status, primary diagnosis and comorbidities correlate with increased odds of TIPS in-hospital death. | Edward Wolfgang Lee Andrew Kuei Sammy Saab Ronald W Busuttil Francisco Durazo Steven-Huy Han Mohamed M El-Kabany Justin P Mc Williams Stephen T Kee | 2016 | World Journal of Gastroenterology2016，22，25： | 7 |
| 4 | Liver transplantation for hepatitis B virus: Decreasing indication and changing trends显示文摘AIM: To evaluate the indication and outcome of hepatitis B virus(HBV)-related liver transplantation(LT) in the era of newer antiviral agents.METHODS: We collected data on all patients who underwent transplantation at King Faisal Specialist Hospital and Research Center.These data included demographic,perioperative and long-term postoperative follow-up data including viral serological markers,HBV DNA,and repeated liver imaging.Between January 1990 and January 2012,133 patients(106 males and 27 females) underwent LT for HBV-related cirrhosis at our center.All patients were followed up frequently during the first year following transplantation,according to our standard protocol; follow-up visits occurred every 3-6 mo thereafter.Breakthrough infection was definedas re-emergence of HBV-DNA or hepatitis B surface antigen(HBs Ag) while on treatment.Five patients transplanted prior to 1992 did not receive immediate posttransplant anti-HBV prophylaxis; all other patients were treated with HBIG and at least one nucleos(t)ide analog.RESULTS: One hundred and thirty-three patients underwent LT for HBV and were followed for a median of 82 mo(range: 1-274).The rates of post-LT survival and HBV recurrence during the follow-up period were 89% and 11%,respectively.The following factors were associated with disease recurrence: younger age(44.3 ± 16.2 years vs 51.4 ± 9.9 years,P = 0.02),positive pretransplant hepatitis B e antigen(HBe Ag)(60% vs 14%,P < 0.0001),detectable pretransplant HBV DNA(60% vs 27%,P = 0.03),positive posttransplant HBs Ag(80% vs 4%,P < 0.0001) and positive posttransplant HBe Ag(27% vs 1%,P < 0.0001).Forty-four(33%) patients had hepatocellular carcinoma(HCC).In the first(pre-2007) group,HBV was the second leading indication for LT after hepatitis C virus infection.A total of 64 transplants were performed,including 46(72%) for decompensated HBV cirrhosis,12(19%) for decompensated cirrhosis complicated by HCC and 6(10%) for compensated cirrhosis complicated by HCC.In the second group,nonalcoholic steatohepatitis surpassed HBV as the second leading indication for LT.A total of 69 HBV related transplants were performed,including 43(62%) for decompensated HBV cirrhosis,7(10%) for decompensated cirrhosis complicated by HCC and 19(27.5%) for compensated cirrhosis complicated by HCC.There was a significant(P = 0.007) increase in the number of transplants for compensated cirrhosis complicated by HCC.CONCLUSION: The use of potent anti-HBV agents has led to a changing trend in the indications for LT.HBV is currently the third leading indication for LT in this hyperendemic area. | Waleed Al-hamoudi Hussien Elsiesy Abdulrahman Bendahmash Nasser Al-masri Safiyya Ali Naglaa Allam Mohammed Al Sofayan Hamad Al Bahili Mohammed Al Sebayel Dieter Broering Sammy Saab Faisal Abaalkhail | 2015 | World Journal of Gastroenterology2015，21，26： | 4 |
| 5 | Evidence-Based Incorporation of Serum Sodium Concentration Into MELD显示文摘 | Scott W. Biggins W. Ray Kim Norah A. Terrault Sammy Saab Vijay Balan Thomas Schiano Joanne Benson Terry Therneau Walter Kremers Russell Wiesner Patrick Kamath Goran Klintmalm | 2006 | Gastroenterology2006，，6： | 3 |
| 6 | A multi‐institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer显示文摘 | Edward J. Kim Edgar Ben‐Josef Joseph M. Herman Tanios Bekaii‐Saab Laura A. Dawson Kent A. Griffith Isaac R. Francis Joel K. Greenson Diane M. Simeone Theodore S. Lawrence Daniel Laheru Christopher L. Wolfgang Terence Williams Mark Bloomston Malcolm J. Moo | 2013 | Cancer2013，，15： | 3 |
| 7 | Sofosbuvir and Ribavirin Prevent Recurrence of HCV Infection after Liver Transplantation: An Open-Label Study显示文摘 | Michael P. Curry Xavier Forns Raymond T. Chung Norah A. Terrault Robert Brown Jonathan M. Fenkel Fredric Gordon Jacqueline O’Leary Alexander Kuo Thomas Schiano Gregory Everson Eugene Schiff Alex Befeler Edward Gane Sammy Saab John G. McHutchison G. Mani S | 2014 | Gastroenterology2014，，： | 3 |
| 8 | Human immunodeficiency virus and nodular regenerative hyperplasia of liver: A systematic review显示文摘AIM: To investigate the diagnosis, pathogenesis, natural history, and management of nodular regenerative hyperplasia(NRH) in patients with human immunodeficiency virus(HIV). METHODS: We performed a systematic review of the medical literature regarding NRH in patients with HIV. Inclusion criteria include reports with biopsy proven NRH. We studied the clinical features of NRH, in particular, related to its presenting manifestation and laboratory values. Combinations of the following keywords were implemented: 'nodular regenerative hyperplasia', 'human immunodeficiency virus', 'noncirrhotic portal hypertension', 'idiopathic portal hypertension', 'cryptogenic liver disease', 'highly active antiretroviral therapy' and 'didanosine'. The bibliographies of these studies were subsequently searched for any additional relevant publications.RESULTS: The clinical presentation of patients with NRH varies from patients being completely asymptomatic to the development of portal hypertension – namely esophageal variceal bleeding and ascites. Liver associated enzymes are generally normal and synthetic function well preserved. There is a strong association between the occurrence of NRH and the use of antiviral therapies such as didanosine. The management of NRH revolves around treating the manifestations of portal hypertension. The prognosis of NRH is generally good since liver function is preserved. A high index of suspicion is required to make a identify NRH. CONCLUSION: The appropriate management of HIVinfected persons with suspected NRH is yet to be outlined. However, NRH is a clinically subtle condition that is difficult to diagnose, and it is important to be able to manage it according to the best available evidence. | Archita Sood Mariana Castrejón Sammy Saab | 2014 | World Journal of Hepatology2014，6，1： | 3 |
| 9 | Long-Term Patient Outcome and Quality of Life After Liver Transplantation: Analysis of 20-Year Survivors显示文摘 | John P. Duffy Kenneth Kao Clifford Y. Ko Douglas G. Farmer Sue V. McDiarmid Johnny C. Hong Robert S. Venick Susan Feist Leonard Goldstein Sammy Saab Jonathan R. Hiatt Ronald W. Busuttil | 2010 | Annals of Surgery2010，，4： | 3 |
| 10 | Risk for Immune-Mediated Graft Dysfunction in Liver Transplant Recipients With Recurrent HCV Infection Treated With Pegylated Interferon显示文摘 | Josh Levitsky Maria Isabel Fiel John P. Norvell Edward Wang Kymberly D. Watt Michael P. Curry Sumeet Tewani Timothy M. McCashland Maarouf A. Hoteit Abraham Shaked Samuel Saab Amanda C. Chi Amy Tien Thomas D. Schiano | 2012 | Gastroenterology2012，，5： | 3 |
| 11 | Effects of Yttrium-90 selective internal radiation therapy on non-conventional liver tumors显示文摘The liver is a common site of metastasis, with essentially all metastatic malignancies having been known to spread to the liver. Nearly half of all patients with extrahepatic primary cancer have hepatic metastases. The severe prognostic implications of hepatic metastases have made surgical resection an important first line treatment in management. However, limitations such as the presence of extrahepatic spread or poor functional hepatic reserve exclude the majority of patients as surgical candidates, leaving chemotherapy and locoregional therapies as next best options. Selective internal radiation therapy(SIRT) is a form of catheter-based locoregional cancer treatment modality for unresectable tumors, involving trans-arterial injection of microspheres embedded with a radioisotope Yttrium-90. The therapeutic radiation dose is selectively delivered as the microspheres permanently embed themselves within the tumor vascular bed. Use of SIRT has been conventionally aimed at treating primary hepatic tumors(hepatocellular carcinoma) or colorectal and neuroendocrine metastases. Numerous reviews are available for these tumor types. However, little is known or reviewed on non-colorectal or nonneuroendocrine primaries. Therefore, the aim of this paper is to systematically review the current literature to evaluate the effects of Yttrium-90 radioembolization on non-conventional liver tumors including those secondary to breast cancer, cholangiocarcinoma, ocular and percutaneous melanoma, pancreatic cancer, renal cell carcinoma, and lung cancer. | Andrew Kuei Sammy Saab Sung-Ki Cho Stephen T Kee Edward Wolfgang Lee | 2015 | World Journal of Gastroenterology2015，21，27： | 2 |
| 12 | Severe Hepatotoxicity Due to Hydroxycut: A Case Report显示文摘 | Michael Shim Sammy Saab | 2009 | Digestive Diseases and Sciences2009，，2： | 2 |
| 13 | A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation显示文摘 | Gregory T. Everson Norah A. Terrault Anna S. Lok Del R. Rodrigo Robert S. Brown Sammy Saab Mitchell L. Shiffman Abdullah M.S. Al‐Osaimi Laura M. Kulik Brenda W. Gillespie James E. Everhart | 2013 | Hepatology2013，，5： | 2 |
| 14 | Pretransplant Model to Predict Posttransplant Survival in Liver Transplant Patients显示文摘 | Rafik M. Ghobrial Jeffery Gornbein Randy Steadman Natale Danino James F. Markmann Curtis Holt Dean Anselmo Farin Amersi Pauline Chen Douglas G. Farmer Steve Han Francisco Derazo Sammy Saab Leonard I. Goldstein Sue V. McDiarmid Ronald W. Busuttil | 2002 | Annals of Surgery2002，，3： | 2 |
| 15 | 运算放大器共模抑制比的测量方法显示文摘 | Alfredo Saab | 2004 | 电子产品世界2004，11，11B： | 2 |
| 16 | Hepatocellular carcinoma screening in patients waiting for liver transplantation: A decision analytic model显示文摘 | Sammy Saab David Ly Jose Nieto Fasiha Kanwal David Lu Steven Raman Rafael Amado Barbara Nuesse Francisco Durazo Steven Han Douglas G. Farmer Rafik M. Ghobrial Hasan Yersiz Pauline Chen Kathy Schwegel Leonard I. Goldstein Myron Tong Ronald W. Busuttil | 2003 | Liver Transplantation2003，，7： | 2 |
| 17 | Structural and Behavioral Synthesis for Testability Techniques显示文摘 | Chen C H Karnik T Saab D G | 1994 | IEEE Transactions on Computer-Aided Design1994，13，6： | 2 |
| 18 | Analysis of Long-term Outcomes of 3200 Liver Transplantations Over Two Decades: A Single-Center Experience显示文摘 | Ronald W. Busuttil Douglas G. Farmer Hasan Yersiz Jonathan R. Hiatt Sue V. McDiarmid Leonard I. Goldstein Sammy Saab Steven Han Francisco Durazo Michael Weaver Carlos Cao Tony Chen Gerald S. Lipshutz Curtis Holt Sherilyn Gordon Jeffery Gornbein Farin Amer | 2005 | Annals of Surgery2005，，6： | 2 |
| 19 | Successful orthotopic liver transplanation forl amivudine-associated YMDD mutant hepatitis B virus显示文摘 | SAAB S KIM M WRIGHT T L | 2000 | Gastroenterology2000，119，5： | 2 |
| 20 | A model to predict the development of mental status changes of unclear cause after liver transplantation显示文摘 | Fasiha Kanwal David Chen Lena Ting Jeffrey Gornbein Sammy Saab Francisco Durazo Hasan Yersiz Douglas Farmer R. Mark Ghobrial Ronald W. Busuttil Steven-Huy Han | 2003 | Liver Transplantation2003，，12： | 2 |
您所在的机构暂未开通此部分的功能，请联系管理员